Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimo Dietrich

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Oncoimmunology|October 23, 2023
<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinomaNiklas Klümper, Lennert Wüst, Jonas Saal, et al.
The Journal of Molecular Diagnostics : JMD|December 26, 2012
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomyDimo Dietrich, Oliver Hasinger, Lionel L Bañez, et al.
JCO Precision Oncology|June 12, 2026
Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyMohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Nature Genetics|April 22, 2014
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumorsGerald Goh, Ute I Scholl, James M Healy, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.
Ebiomedicine|August 30, 2020
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanomaAnne Fröhlich, Judith Sirokay, Simon Fietz, et al.
Clinical Endocrinology|August 8, 2015
Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotypeUte I Scholl, James M Healy, Anne Thiel, et al.
Breast Cancer Research and Treatment|October 30, 2007
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patientsInko Nimmrich, Anieta M Sieuwerts, Marion E Meijer-van Gelder, et al.
Journal of the National Cancer Institute|December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian CancerKonstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
Journal of Medical Genetics|December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Philipp Harter, Corinna Ernst, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Oncoimmunology|October 23, 2023
<i>PD-L1</i> (<i>CD274</i>) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinomaNiklas Klümper, Lennert Wüst, Jonas Saal, et al.
The Journal of Molecular Diagnostics : JMD|December 26, 2012
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomyDimo Dietrich, Oliver Hasinger, Lionel L Bañez, et al.
JCO Precision Oncology|June 12, 2026
Constitutional <i>BRCA1</i> Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyMohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Nature Genetics|April 22, 2014
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumorsGerald Goh, Ute I Scholl, James M Healy, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.
Ebiomedicine|August 30, 2020
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanomaAnne Fröhlich, Judith Sirokay, Simon Fietz, et al.
Clinical Endocrinology|August 8, 2015
Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotypeUte I Scholl, James M Healy, Anne Thiel, et al.
Breast Cancer Research and Treatment|October 30, 2007
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patientsInko Nimmrich, Anieta M Sieuwerts, Marion E Meijer-van Gelder, et al.
Journal of the National Cancer Institute|December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian CancerKonstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
Journal of Medical Genetics|December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in <i>BRCA1/2</i>: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Philipp Harter, Corinna Ernst, et al.
Pageof 12